176 related articles for article (PubMed ID: 8630414)
1. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
[TBL] [Abstract][Full Text] [Related]
2. The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture.
Miller JS; Verfaillie C; McGlave P
Blood; 1992 Nov; 80(9):2182-7. PubMed ID: 1384796
[TBL] [Abstract][Full Text] [Related]
3. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.
Hauch M; Gazzola MV; Small T; Bordignon C; Barnett L; Cunningham I; Castro-Malaspinia H; O'Reilly RJ; Keever CA
Blood; 1990 Jun; 75(11):2250-62. PubMed ID: 2189508
[TBL] [Abstract][Full Text] [Related]
4. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.
Verfaillie C; Miller W; Kay N; McGlave P
Blood; 1989 Aug; 74(2):793-7. PubMed ID: 2473805
[TBL] [Abstract][Full Text] [Related]
5. Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors.
Lotzová E; Savary CA; Champlin RE
J Immunol; 1993 Jun; 150(12):5263-9. PubMed ID: 7685792
[TBL] [Abstract][Full Text] [Related]
6. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma.
Verfaillie C; Blakolmer K; McGlave P
J Exp Med; 1990 Aug; 172(2):509-2. PubMed ID: 2373991
[TBL] [Abstract][Full Text] [Related]
7. T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors.
Bhatia R; McGlave PB
Leukemia; 1995 Jun; 9(6):1006-12. PubMed ID: 7596165
[TBL] [Abstract][Full Text] [Related]
8. Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors.
Agarwal R; Doren S; Hicks B; Dunbar CE
Blood; 1995 Mar; 85(5):1306-12. PubMed ID: 7532038
[TBL] [Abstract][Full Text] [Related]
9. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages.
Bhatia R; McGlave PB; Dewald GW; Blazar BR; Verfaillie CM
Blood; 1995 Jun; 85(12):3636-45. PubMed ID: 7780147
[TBL] [Abstract][Full Text] [Related]
10. Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation.
Verfaillie CM
Blood; 1993 Oct; 82(7):2045-53. PubMed ID: 7691246
[TBL] [Abstract][Full Text] [Related]
11. CD34+/CD33- cells reselected from macrophage inflammatory protein 1 alpha+interleukin-3--supplemented "stroma-noncontact" cultures are highly enriched for long-term bone marrow culture initiating cells.
Verfaillie CM; Miller JS
Blood; 1994 Sep; 84(5):1442-9. PubMed ID: 7520771
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
13. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
14. Role of monocytes in the expansion of human activated natural killer cells.
Miller JS; Oelkers S; Verfaillie C; McGlave P
Blood; 1992 Nov; 80(9):2221-9. PubMed ID: 1421393
[TBL] [Abstract][Full Text] [Related]
15. Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow.
Leemhuis T; Leibowitz D; Cox G; Silver R; Srour EF; Tricot G; Hoffman R
Blood; 1993 Feb; 81(3):801-7. PubMed ID: 7679000
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor.
Miller JS; Alley KA; McGlave P
Blood; 1994 May; 83(9):2594-601. PubMed ID: 7513206
[TBL] [Abstract][Full Text] [Related]
17. The role of natural killer cells in the treatment of chronic myeloid leukemia.
Silla LM; Whiteside TL; Ball ED
J Hematother; 1995 Aug; 4(4):269-79. PubMed ID: 7489141
[TBL] [Abstract][Full Text] [Related]
18. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.
Fujimiya Y; Chang WC; Bakke A; Horwitz D; Pattengale PK
Cancer Immunol Immunother; 1987; 24(3):213-20. PubMed ID: 3496152
[TBL] [Abstract][Full Text] [Related]
19. Chronic myelogenous leukemia: in search of the benign hematopoietic stem cell.
McGlave P; Verfaillie C; Miller J
Stem Cells; 1993 Oct; 11 Suppl 3():10-3. PubMed ID: 7905318
[TBL] [Abstract][Full Text] [Related]
20. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
Verfaillie C; Kay N; Miller W; McGlave P
Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
